Financial Statements · From SEC 10-K & 10-Q XBRL Filings
AbbVie Inc. Revenue & Financial Statements
AbbVie Inc. reported revenue of $61.2B for the fiscal year ended December 31, 2025, up 8.6% year over year, with net income of $4.2B and diluted EPS of $2.36.
- Company
- AbbVie Inc. ABBV · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 56.2B | 58.1B | 54.3B | 56.3B | 61.2B |
| Cost of revenue | 17.4B | 17.4B | 20.4B | 16.9B | 18.2B |
| Gross profit | 10.6B | 11.0B | 8.6B | 10.7B | 12.1B |
| Operating income | 17.9B | 18.1B | 12.8B | 9.1B | 15.1B |
| Pretax income | (1.6B) | (4.6B) | (3.5B) | (7.7B) | 10.1B |
| Net income | 11.5B | 11.8B | 4.8B | 4.2B | 4.2B |
| Diluted EPS | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 |
| EBITDA | 18.7B | 18.9B | 13.5B | 9.9B | 15.8B |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.3B | 14.5B | 14.5B | 15.1B | 13.3B | 15.4B | 15.8B | 16.6B |
| Cost of revenue | 4.1B | 4.2B | 4.2B | 4.4B | 4.0B | 4.3B | 5.3B | 4.6B |
| Gross profit | 8.2B | 10.3B | 10.2B | 10.7B | 9.3B | 11.1B | 10.5B | 12.1B |
| Operating income | 2.8B | 4.0B | 3.8B | (1.5B) | 3.7B | 4.9B | 1.9B | 4.5B |
| Pretax income | 1.8B | 2.1B | 2.1B | (2.3B) | 1.7B | 1.6B | 714.0M | 2.7B |
| Net income | 1.4B | 1.4B | 1.6B | (32.0M) | 1.3B | 928.0M | 176.0M | 1.8B |
| Diluted EPS | 0.77 | 0.77 | 0.88 | -0.02 | 0.72 | 0.52 | 0.10 | 1.02 |
| EBITDA | 3.0B | 4.2B | 4.0B | (1.3B) | 3.9B | 5.1B | 2.1B | 4.7B |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2024 | FY2024 | FY2025 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Total assets | — | 135.2B | — | 134.0B | — |
| Current assets | — | 25.6B | — | 29.1B | — |
| Cash & equivalents | — | 5.5B | — | 5.2B | — |
| Total liabilities | — | — | — | — | — |
| Current liabilities | — | 38.7B | — | 43.3B | — |
| Long-term debt | — | 66.8B | — | 64.5B | — |
| Total debt | — | 66.8B | — | 67.0B | — |
| Stockholders’ equity | — | 3.3B | — | (3.3B) | — |
| Net debt | — | 61.3B | — | 61.8B | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 22.8B | 24.9B | 22.8B | 18.8B | 19.0B |
| Investing cash flow | (2.3B) | (623.0M) | (2.0B) | (20.8B) | (6.6B) |
| Financing cash flow | (19.0B) | (24.8B) | (17.2B) | (5.2B) | (12.7B) |
| Capital expenditure | 787.0M | 695.0M | 777.0M | 974.0M | 1.2B |
| Free cash flow | 22.0B | 24.2B | 22.1B | 17.8B | 17.8B |
| Dividends paid | 9.3B | 10.0B | 10.5B | 11.0B | 11.7B |
| Stock-based compensation | 692.0M | 671.0M | 747.0M | 911.0M | 955.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every ABBV filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.